市場調查報告書

肝炎治療藥市場-成長,趨勢,預測(2020年∼2025年)

Hepatitis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 940583
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
肝炎治療藥市場-成長,趨勢,預測(2020年∼2025年) Hepatitis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

肝炎治療藥市場在預測期間中預計將記錄3.5%的年複合成長率。肝炎是肝臟的發炎或腫大。肝炎發生的原因,是藥物,酒精的使用,以及特定病情。可是,是大部分的情況是病毒引起的病毒性肝炎,A型,B型,C型的3種肝炎有代表性。肝炎是非常常見的疾病,導致肝臟嚴重的疤痕化(肝硬化),可能造成致命的肝功能衰竭。

病毒性肝炎的盛行率增加,肝炎治療藥有前途的開發平台,政府促進患者採用肝炎治療藥的支持性配合措施,成為肝炎治療市場上的主要推動要素。

本報告提供肝炎治療藥市場調查,市場概要,市場成長要素及阻礙因素分析,各疾病類型、各藥物類型、各地區的市場規模的變化與預測,競爭情形,主要企業的簡介,市場機會等全面性資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 病毒性肝炎的盛行率增加
    • 政府為了提高肝炎相關認識的有利支援
    • 技術性進步提高治療產品的可用性
  • 市場阻礙因素
    • 嚴格法規問題
    • 不完全的償付方針
  • 波特的五力分析

第5章 市場細分化

  • 各疾病類型
    • A型肝炎
    • B型肝炎
    • C型肝炎
    • D型肝炎
    • 其他類型
  • 各藥物類別
    • 干擾素
    • 單株抗體
    • 非結構蛋白質5A(NS5A)抑制劑
    • 核苷酸類比逆轉錄酵素抑制劑
    • 核苷酸類比NS5B聚合酵素抑制劑
    • 多級的組合
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Merck & Co., Inc
    • Gilead Sciences, Inc
    • AbbVie Inc
    • Bristol Myers Squibb Company
    • F. Hoffmann-La Roche, Ltd
    • LAURUS Labs
    • Zydus Cadila
    • Hetero Healthcare Limited
    • NATCO Pharma Limited
    • Cipla, Inc

第7章 市場機會及未來趨勢

目錄
Product Code: 67936

The Hepatitis Therapeutics Market is expected to register a CAGR of 3.5% during the forecast period. Hepatitis is an inflammation, or swelling, of the liver. Hepatitis may occur due to drugs, alcohol use, or certain medical conditions. But in most of the cases, it is caused by a virus called viral hepatitis, and the most common forms are hepatitis A, B, and C. Hepatitis is a very common disease and can lead to serious scarring (cirrhosis) of the liver and liver failure, which can be fatal.

Some of the common symptoms of hepatitis are loss of appetite, nausea and vomiting, fatigue, fever, body aches, and stomach pain. Some people may experience light-colored bowel movements, dark urine, and yellowing of the skin or of the eyes (jaundice). Viral infections of the liver are classified as hepatitis A, B, C, D, and E. A different virus is responsible for each type of virally transmitted hepatitis. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are mostly ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women. Hepatitis can be diagnosed through history and physical exam, liver function tests, blood tests, and ultrasound. Some of the complications of hepatitis B or C are chronic liver disease, cirrhosis, and liver cancer.

According to the World Health Organization (WHO), globally, 500 million people are estimated to be infected with hepatitis B or C. About 1.5 million people die in a year due to hepatitis infection, 1 in every 3 people get infected and most of the infected people do not know about it due to dormant symptoms. In addition, in European Hepatitis B and C affect millions of people. In addition, According to the European Centre for Disease Prevention and Control (ECDC), estimates an overall incidence of hepatitis B is 1.49 (Per 100,000), hepatitis c is 8.7 (Per 100,000) in the member states of the European Union (EU) and high prevalence in people who inject drugs.

An increase in the prevalence of viral hepatitis, promising pipeline of hepatitis drugs, and supportive government initiatives encouraging patients in the adoption of hepatitis drugs are the key driving factors in the hepatitis therapeutics market.

Key Market Trends

Hepatitis C Segment is Expected to Hold a Major Market Share in the Hepatitis Therapeutics Market

  • Hepatitis C is a liver infection which is caused by the hepatitis C virus. Hepatitis C can range from a mild to serious and lifelong illness. Acute hepatitis C occurs within the first 6 months after individual is exposed to the hepatitis C virus and chronic hepatitis C can be a lifelong infection with the hepatitis C virus if left untreated.
  • According to World Health Organization (WHO), hepatitis C virus (HCV) infection affects over 70 million people globally, and about 3.5 million Americans have hepatitis C virus (HCV) infection among them approximately 3.2 million have chronic (long-term) infection.
  • Hepatitis C segment holds a significant market share in the hepatitis therapeutics market and is anticipated to show a similar trend over the forecast period due to the high prevalence of hepatitis C in developing and developed regions and the growing availability of effective drug regimens in the market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the hepatitis therapeutics market due to an increase in the incidence of hepatitis, mortality due to hepatitis and increased spending on drugs for the treatment of hepatitis in this region. According to the Center for Disease Control (CDC), estimates about 2.4 million people are living with hepatitis C in the United States and approximately 850,000 people in this region estimated to be living with hepatitis B. In addition, 67% of persons infected with hepatitis B virus do not know they have the virus. Furthermore, favorable reimbursement policies, high adoption rates of advance therapeutics and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Hepatitis Therapeutics Market is fragmented competitive and consists of several major players. However, in terms of market share, few of the major players are currently dominating the market. Some of the leading market players include Merck & Co., Inc, Gilead Sciences, Inc, AbbVie Inc, Bristol Myers Squibb Company, F. Hoffmann-La Roche, Ltd, LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, NATCO Pharma Limited and Cipla, Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Viral Hepatitis
    • 4.2.2 Favorable Government Support for Creating Awareness about Hepatitis
    • 4.2.3 Increasing Availability of Technologically Advanced Therapeutic Products
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Issues
    • 4.3.2 Poor Reimbursement Policies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Disease Type
    • 5.1.1 Hepatitis A
    • 5.1.2 Hepatitis B
    • 5.1.3 Hepatitis C
    • 5.1.4 Hepatitis D
    • 5.1.5 Other Types
  • 5.2 By Drug Class
    • 5.2.1 Interferon
    • 5.2.2 Monoclonal Antibody
    • 5.2.3 Non-structural protein 5A (NS5A) inhibitors
    • 5.2.4 Nucleotide Analog Reverse Transcriptase Inhibitors
    • 5.2.5 Nucleotide Analog NS5B Polymerase Inhibitors
    • 5.2.6 Multi Class Combination
    • 5.2.7 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East-and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Merck & Co., Inc
    • 6.1.2 Gilead Sciences, Inc
    • 6.1.3 AbbVie Inc
    • 6.1.4 Bristol Myers Squibb Company
    • 6.1.5 F. Hoffmann-La Roche, Ltd
    • 6.1.6 LAURUS Labs
    • 6.1.7 Zydus Cadila
    • 6.1.8 Hetero Healthcare Limited
    • 6.1.9 NATCO Pharma Limited
    • 6.1.10 Cipla, Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS